Lexeo Therapeutics, Inc. Common Stock (LXEO)

USD 6.36

(-8.62%)

Market Cap (In USD)

210.29 Million

Revenue (In USD)

-

Net Income (In USD)

-66.39 Million

Avg. Volume

351.93 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.77-22.33
PE
-
EPS
-
Beta Value
0.0
ISIN
US52886X1072
CUSIP
52886X107
CIK
1907108
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. R. Nolan Townsend
Employee Count
-
Website
https://www.lexeotx.com
Ipo Date
2023-11-03
Details
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.